ADAMTS13 and thrombotic thrombocytopenic purpura: Furthermore, the International Society on Thrombosis and Haemostasis (ISTH) guidelines recommend Rituximab and caplacizumab ought to be contemplated for patients exhibiting a high likelihood of TTP and those for whom ADAMTS13 test results are attainable [17], in this case, the patient was not treated with caplacizumab because there is no such monoclonal antibody in Honduras.